Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics
Oxford, UK – 5 January 2023 Celleron Therapeutics and Argonaut Therapeutics have jointly announced today the completion of a merger
Search Results for:
Celleron Therapeutics founder David Kerr CBE receives major Chinese award
Oxford, UK, 08 Nov 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that
Celleron Therapeutics Co-founder Professor David Kerr awarded Fellowship of ESMO
Oxford, UK, 22 Sep 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that
Celleron Therapeutics partnered programme receives funding for investigating zabadinostat in immune checkpoint inhibitor resistant liver cancer
Oxford, UK, 15 August 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announces today that in
Celleron Therapeutics reports 3-year survival data from Phase II clinical trial in MSS colorectal cancer patients treated with zabadinostat and nivolumab combination
Oxford, UK, 29 June 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announced today a 3-year
Celleron Therapeutics reports over 2-year survival of cancer patient treated with zabadinostat monotherapy
Oxford, UK, 7 April 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a
Anti-Slavery Statement
Anti-Slavery Statement Modern slavery is a crime and a violation of fundamental human rights. It takes various forms, all of
Celleron Therapeutics reports survival data from zabadinostat combined with nivolumab in micro-satellite stable colorectal cancer patients
Oxford UK, 20 January 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a
Celleron Therapeutics Deploys a Digital Pathology Biomarker Platform in Pivotal Colorectal Cancer Clinical Study
Oxford, UK, 30 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the adoption
Celleron Therapeutics Appoints Corporate Governance Expert, Katherine Innes Ker, To Board
Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the